dc.contributor.author | Ekanayake Weeramange, C | |
dc.contributor.author | Liu, Z | |
dc.contributor.author | Hartel, G | |
dc.contributor.author | Li, Y | |
dc.contributor.author | Vasani, S | |
dc.contributor.author | Langton-Lockton, J | |
dc.contributor.author | Kenny, L | |
dc.contributor.author | Morris, L | |
dc.contributor.author | Frazer, I | |
dc.contributor.author | Tang, KD | |
dc.contributor.author | Punyadeera, C | |
dc.date.accessioned | 2021-11-17T05:11:22Z | |
dc.date.available | 2021-11-17T05:11:22Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1525-1578 | |
dc.identifier.doi | 10.1016/j.jmoldx.2021.07.005 | |
dc.identifier.uri | http://hdl.handle.net/10072/410178 | |
dc.description.abstract | High-risk human papillomavirus (HR-HPV) infection is a major risk factor of head and neck cancers (HNCs). Despite the rising prevalence of HPV-driven HNC (HPV-HNC), biomarkers for detection, prognostication, and disease monitoring are lacking. To evaluate the capacity of salivary HR-HPV DNA as a biomarker of HPV-HNC, the salivary HR-HPV statuses of 491 and 10 patients with primary and recurrent HNC, respectively, were determined at diagnosis, using quantitative real-time PCR and MassARRAY. Tumor cyclin-dependent kinase inhibitor 2A (p16) expression was determined by IHC analysis. Patients with oropharyngeal cancer (OPC) (n = 215) were followed up for ≤5 years. Survival characteristics were evaluated in terms of event-free and cause-specific survival. Of the primary-HNC cohort, 43.2% were positive for salivary HR-HPV DNA, with most having OPC. Salivary HR-HPV DNA was detected in 81.4% of tumor p16–positive OPC patients at diagnosis. Prognosis in salivary HR-HPV–positive OPC patients was favorable compared with that in salivary HR-HPV–negative patients (event-free survival, hazard ratio = 0.42 [95% CI, 0.21–0.81, P = 0.010]; cause-specific survival, hazard ratio = 0.39 [95% CI, 0.18–0.86, P = 0.019]). In the recurrent-HNC cohort, salivary HR-HPV DNA was detected in 83.3% of those who previously had tumor p16–positive HNC. These findings indicate that this liquid biopsy–based, noninvasive biomarker can play an essential role in the detection and management of HPV-HNC. | |
dc.description.peerreviewed | Yes | |
dc.language | eng | |
dc.publisher | Elsevier BV | |
dc.relation.ispartofpagefrom | 1334 | |
dc.relation.ispartofpageto | 1342 | |
dc.relation.ispartofissue | 10 | |
dc.relation.ispartofjournal | Journal of Molecular Diagnostics | |
dc.relation.ispartofvolume | 23 | |
dc.subject.fieldofresearch | Medical microbiology | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearch | Oncology and carcinogenesis | |
dc.subject.fieldofresearchcode | 3207 | |
dc.subject.fieldofresearchcode | 3202 | |
dc.subject.fieldofresearchcode | 3211 | |
dc.title | Salivary High-Risk Human Papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck Cancers | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Ekanayake Weeramange, C; Liu, Z; Hartel, G; Li, Y; Vasani, S; Langton-Lockton, J; Kenny, L; Morris, L; Frazer, I; Tang, KD; Punyadeera, C, Salivary High-Risk Human Papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck Cancers, Journal of Molecular Diagnostics, 2021, 23 (10), pp. 1334-1342 | |
dcterms.dateAccepted | 2021-07-08 | |
dc.date.updated | 2021-11-17T05:10:47Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Punyadeera, Chamindie | |
gro.griffith.author | Ekanayake Weeramange, Chameera | |